10-Q
Quarterly Report
ADIAL PHARMACEUTICALS, INC.
ADILW
NASDAQ
CIK: 1513525
File #: 001-38323
Balance Sheet
37 line items · 2 periods
XBRL
| Item | Sep 30, 2023 | Dec 31, 2022 |
|---|---|---|
Current Assets: | ||
Cash and cash equivalents | 315,880 | 4,001,794 |
Purnovate sale payments receivable | 350,000 | — |
Prepaid expenses and other current assets | 469,606 | 349,441 |
Current assets of discontinued operations | — | 428,700 |
Total Current Assets | 1,135,486 | 4,779,935 |
Discontinued Operations | — | 428,700 |
Intangible assets, net | 4,054 | 4,477 |
Equity method investment | 1,727,897 | — |
Assets of discontinued operations | — | 948,392 |
Total Assets | 2,867,437 | 5,732,804 |
Discontinued Operations | — | 1,377,092 |
LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
Current Liabilities: | ||
Accounts payable | 81,925 | 276,410 |
Discontinued Operations | — | 117,424 |
Accrued expenses | 408,614 | 963,327 |
Discontinued Operations | — | 191,490 |
Accrued expenses, related party | 30,000 | 175,000 |
Other current liabilities | 7,640 | 10,387 |
Current liabilities of discontinued operations | — | 365,742 |
Total Current Liabilities | 528,179 | 1,790,866 |
Discontinued Operations | — | 365,742 |
Long-term Liabilities: | ||
Deferred tax liability | — | 1,690 |
Long-term liabilities of discontinued operations | — | 663,754 |
Total Liabilities | 528,179 | 2,456,310 |
Discontinued Operations | — | 1,029,496 |
Stockholders’ Equity | ||
Common Stock, 50,000,000 shares authorized with a par value of $0.001 per share, 1,217,981 and 1,067,491 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively | 1,218 | 1,067 |
Additional paid in capital | 69,215,579 | 66,949,958 |
Accumulated deficit | (66,877,539) | (63,674,531) |
Total Stockholders’ Equity | 2,339,258 | 3,276,494 |
Common Stock | 1,218 | 1,067 |
Additional Paid In Capital | 69,215,579 | 66,949,958 |
Accumulated Deficit | (66,877,539) | (63,674,531) |
Total Liabilities and Stockholders’ Equity | 2,867,437 | 5,732,804 |